aureus in early infancy. Serial nasal swabs were collected from 128 infants and their mothers at months 0, 6, and 12 postpartum. S. aureus isolates

were characterized by pulsed-field gel electrophoresis (PFGE), multilocus sequence typing (MLST), spa typing, and the presence of chromosomal mecA and of Panton-Valentine leukocidin (PVL) genes. S. aureus was isolated in 17.7% and 15.7% of swabs from infants and mothers, respectively. Carriage rates were higher in infants with carrier mothers, non-smoking mothers, and many siblings. Persistent carriage rates were higher in infants with carrier or non-smoking mothers. S. aureus typing revealed identical strains in 10/15 investigated infant-mother pairs. Among 19 investigated S. aureus isolates from infants, ten EVP4593 harbored mecA and two harbored PVL genes, and these determinants were concomitantly present in isolates from selleck compound mothers. Resistance

to methicillin was 43.6% among all isolates from infants. In conclusion, isolates from infants were commonly identical to isolates from their mothers, pointing to a principal role of maternal carriage in S. aureus colonization in infants.”
“The effects of the selective cyclooxygenase (COX) inhibitors SC-560 and PTPBS were studied in Chlamydia pneumoniae-infected HL cell cultures. Chlamydia pneumoniae growth and viability were assessed by quantifying inclusions and re-passages. COX-1 and COX-2 mRNA

expression in HL cells during chlamydial infection was quantified with real-time polymerase chain reaction. SC-560 (10 mu g/mL) and PTPBS (18 mu g/mL) completely inhibited the growth of C. pneumoniae and the effect was dose-dependent between 4-9 mu g/mL and 2-16 mu g/mL, respectively. Inclusion size was reduced from 11.5 +/- 1.3 mu m to 1.9 +/- 0.7 mu m in the presence of the drugs. Removing the drugs returned the size to normal and increased the number of inclusions. Selective COX inhibitors GDC-0941 price appear to have a chlamydiostatic but not chlamydiacidic effect: they inhibit the growth of C. pneumoniae in vitro but do not prevent infection or eradicate C. pneumoniae from host cells. 2008 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.”
“Inflammatory cells are involved in tumour initiation and progression. In parallel, the adaptive immune response plays a key role in fighting tumour growth and dissemination. The double-edged role of the immune system in solid tumours is well represented in colorectal cancer (CRC). The development and progression of CRC are affected by the interactions between the tumour and the host’s response, occurring in a milieu named tumour microenvironment. The role of immune cells in human CRC is being unravelled and there is a strong interest in understanding their dynamics as to tumour promotion, immunosurveillance and immunoevasion.